(MedPage Today) — The FDA approved ropeginterferon alfa-2b (Besremi) injection to treat adults with essential thrombocythemia, the first new therapy for the chronic blood cancer since the 1997 approval of anagrelide.
A national survey showed…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
